التفاصيل البيبلوغرافية
| العنوان: |
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. |
| المؤلفون: |
Weber, Jeffrey S., Postow, Michael, Lao, Christopher D., Schadendorf, Dirk |
| المصدر: |
Oncologist; Oct2016, Vol. 21 Issue 10, p1230-1240, 11p, 2 Color Photographs, 1 Diagram, 2 Charts |
| مصطلحات موضوعية: |
PREVENTION of drug side effects, ENDOCRINE diseases, GASTROINTESTINAL diseases, HEPATOTOXICOLOGY, IMMUNOTHERAPY, LUNG diseases, MELANOMA, MONOCLONAL antibodies, PANCREATITIS |
| مستخلص: |
Immune checkpoint inhibitors have emerged as a mainstay of melanoma therapy and are playing an increasingly important role in the treatment of other tumor types. The clinical benefit afforded bythese treatments can be accompanied bya unique spectrum of adverse events, called immune-related adverse events (irAEs), which reflect the drug's immune-based mechanism of action. IrAEs typically originate in the skin, gastrointestinal tract, liver, and endocrine system, although other organ systems may also be affected.This article provides an overview of irAEs associated with anti-programmed death-1 (anti-PD-1) antibodies (nivolumab and pembrolizumab) as monotherapy or in combination with anti-cytotoxic T-lymphocyte antigen-4 inhibition (ipilimumab), followed by a discussion of irAEs of special clinical interest based on the potential for morbidity, frequent steroid use, and inpatient admission. We review clinical trial data and provide recommendations on how to manage irAEs associated with anti-PD-1 agents based on clinical experience and established management guidelines. We further illustrate the practical considerations of managing irAEs by presenting three cases of immune-related toxicity in melanoma patients treated with nivolumab or pembrolizumab. A better understanding of the identification and management of irAEs will help inform health care providers about the risks associated with anti-PD-1 treatment, to ensure the safe and appropriate use of these important new treatments. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder